Almost all of Novo’s 250 cell therapy employees will be laid off, Fierce reported, citing the Danish outlet Borsen.
All entries for: Biologic
October 14, 2025
Novo Nordisk
Layoffs
Bagsværd
10,000+ employees
Disease Area: Chronic Disease, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
October 10, 2025
Ferring Pharmaceuticals
Layoffs
Saint-Prex, Switzerland
5,001-10,000 employees
Privately held Ferring Pharmaceuticals will part ways with up to 500 employees across its global operations in a bid to “sharpen” its strategic focus and gain “flexibility” as a company. The layoffs will mean an approximately 7% headcount reduction.
Disease Area: Endocrinology, Gastrointestinal, Hematology, Oncology
Drug Type: Biologic, Small Molecule
October 7, 2025
Pharming
Layoffs
Netherlands
201-500 employees
In a bid to accelerate its growth, Netherlands-based Pharming has implemented an organization restructuring initiative that will involve a 20% reduction in headcount. These latest layoffs could impact roughly 81 workers. Pharming has indicated that the terminations will focus on its non-commercial and non-medical staff.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
October 3, 2025
Bolt Biotherapeutics
Layoffs
Redwood City, CA
51-200 employees
In an effort to extend its runway into 2027, California’s Bolt Biotherapeutics will let go of 50% of its employees. Around 20 workers will be affected, according to an SEC document, with the layoffs expected to be complete by the end of the year.
Disease Area: Oncology
Drug Type: Biologic
October 3, 2025
Takeda
Layoffs
Tokyo
10,000+ employees
Takeda is laying off 137 employees. According to an Oct. 1 Worker Adjustment and Retraining Notification (WARN) Act notice, those staffers, located in Cambridge, Massachusetts, are being let go effective Jan. 1 through July 31, 2026.
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
October 2, 2025
GSK
Layoffs
London, UK
10,000+ employees
Pharma giant GSK continues to shed employees, this time with an 8-person round of layoffs at its San Francisco, California site, according to a Worker Adjustment and Retraining Notification posting. The terminations were effective Sept. 29. GSK has enacted a couple of other workforce reductions this year.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
October 1, 2025
Sutro
Layoffs
South San Francisco, CA
201-500 employees
Sutro Biopharma is letting go of one third of its workforce. The South San Francisco–based company will use the money saved to focus on three antibody-drug conjugate programs, as well as its research and development collaborations. This is the second large-scale layoff for Sutro this year.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
September 29, 2025
Heidelberg Pharma
Layoffs
Ladenburg, Germany
51-200 employees
Ladenburg, Germany–based Heidelberg Pharma is laying off 75% of its staff after the company failed to meet the conditions for a royalty payment. Without the $70 million that royalty would have netted, Heidelberg is downsizing to extend its runway and focus its pipeline. The company has 122 employees, according to a May press release, so up to 92 employees will be affected. Heidelberg did not specify what conditions it missed, but in a financing agreement with HealthCare Royalty, Royalty would pay $70 million upon FDA approval of TLX250-CDx, Heidelberg’s radiolabeled version of the antibody girentuximab for clear cell renal cell carcinoma.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
September 23, 2025
Seres Therapeutics
Layoffs
Cambridge, MA
51-200 employees
As part of cost-cutting measures to support its lead program, Seres Therapeutics is laying off about 25% of its workforce, which includes people let go effective in August.Seres expects the cuts will help extend its cash runway into the second quarter of 2026.
Disease Area: Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic
September 19, 2025
Bristol Myers Squibb
Layoffs
Lawrence Township, NJ
10,000+ employees
Bristol Myers Squibb is letting go of 282 employees in Lawrenceville, New Jersey, with effective dates in December 2025 and February and March of next year.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule